About Us

Alnylam Pharmaceuticals is a global leader in RNA interference (RNAi) therapeutics, transforming Nobel Prize-winning science into innovative medicines for people with serious and rare genetic diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has developed and commercialized several first-in-class RNAi-based treatments, including ONPATTRO®, GIVLAARI®, OXLUMO®, and AMVUTTRA®, addressing conditions such as hereditary amyloidosis and acute hepatic porphyria.

Driven by the mission to “Silence Disease. Amplify Life.™”, Alnylam is committed to advancing genetic medicine and improving patient outcomes worldwide. With a strong focus on scientific innovation, patient advocacy, and community engagement, Alnylam continues to expand its reach and impact in the biopharmaceutical industry.

Scroll to Top